At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 43 enrolled
Drug / intervention
Pazopanib (GW786034) +1 moredrug
Likely dose
Pazopanib (GW786034) 800mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
In Brief
A Phase 2 clinical trial evaluating Pazopanib (GW786034) and Paclitaxel for Bladder Cancer and 4 related conditions. Completed, enrolled 43 participants across 2 sites.
Detailed Summary
We will combine an oral investigational vascular endothelial growth factor (VEGF inhibitor) called pazopanib which is being studied in kidney cancer will be combined with standard chemotherapy called taxol in patients with relapsed recurrent urothelial cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBladder Cancer, Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy), Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable
CountriesUnited States
CollaboratorsGlaxoSmithKline
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2010
First PostedApr 2010
Primary CompletionJan 2015
Study CompletionJul 2015
TodayJul 2026
First PostedApr 21, 2010
Enrollment StartApr 1, 2010
Primary CompletionJan 1, 2015
Study CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 16.2 years ago
Interventions
Pazopanib (GW786034)drug
Cycle of 28 days. Pazopanib: 800mg/day
Paclitaxeldrug
Cycle of 28 days Paclitaxel: 80mg/m2 days 1,8 and 15